The regain is associated with an increase in risk factors for cardiometabolic conditions like diabetes and heart disease
Certain conditions may be treated via message-based (asynchronous) care
It should be based on your health and what doctors say
Preliminary animal studies suggest that GLP-1 receptor agonists may modulate dopaminergic signaling in brain regions associated with reward and motivation, including the nucleus accumbens and ventral tegmental area
Data from animal studies further suggest that the appetite suppressant (anorectic) effects of GLP-1R agonists are also manifested through mesolimbic GLP-1R activation, that in turn alters the rewarding value of food [23,24,25,26,27,28,29]
Ruining a peptide protocol because you tried to stretch a BAC water vial past its limit costs significantly more